ST Pharm Co.,Ltd.

KOSDAQ 237690.KQ

ST Pharm Co.,Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 63.54 M

ST Pharm Co.,Ltd. Net Cash Used Provided By Financing Activities is USD 63.54 M for the year ending December 31, 2023, a 585.21% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • ST Pharm Co.,Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 9.27 M, a 1,456.97% change year over year.
  • ST Pharm Co.,Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD -683.35 K, a -100.64% change year over year.
  • ST Pharm Co.,Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 106.82 M, a 2,195.26% change year over year.
  • ST Pharm Co.,Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 4.65 M, a 157.80% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
KOSDAQ: 237690.KQ

ST Pharm Co.,Ltd.

CEO Mr. Geun-Jo Im Ph.D.
IPO Date June 23, 2016
Location South Korea
Headquarters MSA Building
Employees 566
Sector Health Care
Industries
Description

ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It also provides oligonucleotide based products, such as antisense, siRNA, miRNA, aptamer, CpG, decoy, and other products; and monomer/phosphoramidite. In addition, the company offers generic APIs for anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppressant, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medicines, as well as MRI contrast agents. Further, it provides 2nd battery, electronic materials, and polymer catalysts. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is based in Seoul, South Korea.

Similar companies

196170.KQ

ALTEOGEN Inc.

USD 209.72

3.60%

207940.KS

Samsung Biologics Co.,Ltd.

USD 698.37

1.93%

068270.KS

Celltrion, Inc.

USD 125.83

1.12%

006280.KS

Green Cross Corporation

USD 108.37

-2.33%

StockViz Staff

January 15, 2025

Any question? Send us an email